Associated Press (11.16.09) - Thursday, November 19, 2009
Randolph E. Schmid

The adenovirus serotype 5 (Ad5) was used as a vector to carry genetic HIV material that researchers hoped would prompt an immune response to prevent HIV's spread. Because adenovirus is a common cold virus, many people have been previously exposed to it, including some STEP trial participants.

In the new study, investigators proposed that increased HIV infection rates among Ad5-seropositive vaccine recipients "was due to activation and expansion of Ad5-specific mucosal-homing memory CD4 T cells." In these individuals, mucous membranes could have produced large numbers of CD4 cells, providing HIV with an abundance of the very cells the virus infects.

"Our research would suggest a cautious approach for the future development of adenovirus vector vaccines for use in areas of high HIV prevalence, or in individuals whose lifestyles meant that they were at higher risk of HIV infection," said Steven Patterson, the study's lead author.

"If our hypothesis is correct, then the use of an adenovirus vaccine against any disease in an area of high HIV prevalence may increase risk of HIV infection," Patterson said. On the other hand, "there are scientists in the HIV vaccine field who do not believe that the adenovirus was the reason for increased number of infections in the vaccinated group."

"It would be premature to suggest that this provides an explanation for the STEP results, and the implications for other vaccines or gene therapy are unclear," Dr. Michael Robertson, director of Infectious Diseases/Vaccines Clinical Research at Merck, said through a spokesperson.

The full study, "Adenovirus Vector Vaccination Induces Expansion of Memory CD4 T Cells with a Mucosal Homing Phenotype that Are Readily Susceptible to HIV-1," was published in the Proceedings of the National Academy of Sciences (2009;doi: 10.1073/pnas.0907898106).
091119
AD091988

Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.